Navigation Links
USC researchers identify novel approach for suppressing prostate cancer development
Date:11/24/2008

Los Angeles, Calif. Nov. 24, 2008Researchers at the University of Southern California (USC) have found that inactivating a specific biomarker for aggressive prostate cancer blocks the development of prostate cancer in animal models.

Researchers say the upcoming study in the Proceedings of the National Academy of Sciencesnow available onlinemay lead to a novel cancer therapy for humans.

"This research has far-reaching implications in a wide range for human cancers," says Amy Lee, Ph.D., the study's principal investigator and the associate director for basic research and holder of the Freeman Cosmetics Chair at the USC/Norris Comprehensive Cancer Center, and professor of biochemistry and molecular biology at the Keck School of Medicine of USC. "It is a breakthrough study."

Prostate cancer is the most common cancer in men and develops through successive stages. The glucose-regulated protein GRP78 has been identified as a crucial entity in the development of prostate cancer by promoting cancer cell proliferation, mediating oncogenic signaling and protecting cancer cells against cell death resulting from the stress of tumor development, Lee explains. By suppressing GRP78 expression or activity, the USC researchers found that they could block prostate cancer activation and development resulting from the loss of PTEN, a powerful tumor suppressor gene for a number of human cancers.

Researchers spent more than three years monitoring prostate cancer development in animal models that had been genetically engineered to have both the GRP78 and PTEN tumor suppressor genes inactivated. The research was conducted by Yong Fu, a Ph.D. candidate at the Keck School of Medicine of USC and the first author on the study, in collaboration with Ph.D candidates Shiuan Wey, Miao Wang, Risheng Ye and Chun-Peng Liao and Pradip Roy-Burman, M.D., professor of pathology, biochemistry and molecular biology at the Keck School.

Future research should test the role of GRP78 in other types of cancer and isolate drugs that inhibit GRP78, Lee says. "To our knowledge, this is the first demonstration that inactivation of a specific molecular chaperone from the mouse prostate epithelial cells can potently block prostate cancer development and suppress the activation of AKT, which is a protein kinase that promotes cell proliferation and survival and is a major factor in many types of cancer," Lee says. "With the recent advances in identifying agents that suppress GRP78 expression, anti-GRP78 therapy may open up an entirely new approach to stop human cancer."


'/>"/>

Contact: Meghan Lewit
lewit@usc.edu
323-442-3941
University of Southern California
Source:Eurekalert

Related medicine news :

1. Researchers identify new leprosy bacterium
2. UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
3. Researchers discover strategy for predicting the immunity of vaccines
4. Ability to quit smoking may depend on ADHD symptoms, Columbia researchers find
5. Researchers ID Suite of Genes in Aging Process
6. Researchers: Ban on fast food TV advertising would reverse childhood obesity trends
7. Brigham and Womens Researchers Partner with Vocantas to use CallAssure in Clinical Research Study
8. Leeds researchers reshape the future of drug discovery
9. UNC researchers find clue to stopping breast-cancer metastasis
10. U of U researchers to use patients own stem cells to treat heart failure
11. Researchers identify toehold for HIVs assault on brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Using the power of ... a simple online checklist. Over a period of just 24 months, thousands of individuals ... an online checklist called T.A.D. , “The internet is not getting quieter. In fact ...
(Date:2/22/2017)... ... February 22, 2017 , ... ANGLESTRONG , the new recovery ... available on the App Store and Google Play . Florida-based Sober ... addiction and recovery industry, partnered with Angle to build ANGLESTRONG. The new recovery management ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... related to spine practices, is featuring Michigan neurosurgeon Jay Jagannathan, M.D., as a ... of a small number of neurosurgeons in Michigan performing minimally invasive back surgery ...
(Date:2/22/2017)... PA (PRWEB) , ... February 22, 2017 , ... A ... some people seem to derive a heart-protective benefit from eating soy foods, while others ... , Japanese men who are able to produce equol—a substance made by some types ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... hearing and 72 percent of those report that family members or friends have ... think they suffer from hearing loss wear hearing aids. One reason, suggested by ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... 2017  Bioness, Inc., the leading provider of cutting ... series of successful StimRouter Neuromodulation System implantations in ... (Nijmegen, Netherlands ), South ... ), and Kliniek Park Leopold Chirec ( Brussels, ... plans to further support clinicians across the continent who ...
(Date:2/22/2017)... Colo. , Feb. 22, 2017  Aytu BioScience, ... global commercialization of novel products in the field of ... team to up to 42 account managers from 35 ... The sales force expansion is being ... prescriptions and revenues, an indication of increasing acceptance of ...
(Date:2/22/2017)... -- According to a new market research report "Process Analytical ... Services (Analyzers, Probes & Sensors), End - User (Pharmaceutical Manufacturers, CRO & ... is poised to reach USD 3.30 Billion by 2021 from USD 1.77 ... Continue Reading ... ...
Breaking Medicine Technology: